KC RegisterAllergan to pay Editas $90m for development of CRISPR eye treatmentLife Sciences Intellectual Property Review (subscription)Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and develo… Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesYahoo FinanceCAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today an… Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesGlobeNewswire (press release)CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging … Continue reading
Cellaria Adds Next-Generation RNA Reprogramming and Stem Cell ServicesGlobeNewswire (press release)CAMBRIDGE, Mass., March 20, 2017 (GLOBE NEWSWIRE) — Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging … Continue reading
|
Cesca Therapeutics (KOOL) Announces CLI Feasibility Study Published in Stem Cells International
StreetInsider.com The report was published in the “Stem Cells International” and is available online at https://www.hindawi.com/journals/sci/2017/4137626/ref/. Results from the seventeen patient clinical study titled, “Safety and Effectiveness of Bone Marrow Cell … |
|
Start your engineering — CARs take to the TRAC
Nature.com T cells genetically engineered to express chimeric antigen receptors (CARs) that recognize tumour-associated antigens are promising anticancer agents. In particular, anti-CD19 CAR T cells can induce complete remission in patients with B-cell malignancies. |